Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

This study has been completed.
Weill Medical College of Cornell University
Brigham and Women's Hospital
University of Cologne
Information provided by (Responsible Party):
Rockefeller University Identifier:
First received: December 17, 2013
Last updated: February 1, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):